INCYIncyte

Healthcare

$112.81+31% 1Y

$112.81

$81.6652 weeks$129.88

Is the price fair?

Good

Undemanding: cheap against its own history and cheap vs its sector.

2 good, 1 without data

Vs its own P/E rangecheaper than 85% of its own historyderived

Cheap vs its own history: P/E 15.9 vs a 38.4 median over 27 quarters (−59% vs median).

Vs sector (EV/EBIT)10.9×derived · Dec 31, 2025

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)better than 67% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What INCY's price assumes

Incyte trades at 15.9× earnings against 18.8× for the median Biotechnology name, cheaper than its own group.

15.9

Trailing P/E · Biotechnology median 18.8 · cheaper than the typical name in its group

Price / sales: 3.82
Price / sales · today's price, fiscal year to Dec 31, 2025
Price / book: 3.80
Price / book · today's price, fiscal year to Dec 31, 2025
EV / sales: 3.21
EV / sales